Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma

Next Previous
Trial Profile

A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GPC3-CAR-T (Primary) ; Antineoplastics; Cyclophosphamide; Fludarabine; Protein tyrosine kinase inhibitors
  • Indications Liver cancer
  • Focus Adverse reactions

Most Recent Events

  • 21 Aug 2021 Status changed from recruiting to completed.
  • 10 Oct 2019 Status changed from not yet recruiting to recruiting.
  • 25 Jul 2019 Planned initiation date changed from 30 Jun 2019 to 26 Jul 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top